Literature DB >> 7720171

Detoxification ability and toxicity of quinones in mouse and human tumor cell lines used for anticancer drug screening.

Z Djuric1, T H Corbett, F A Valeriote, L K Heilbrun, L H Baker.   

Abstract

The in vitro testing of antitumor drugs involves the use of mouse and human tumor cells. In particular, there is interest in developing agents active against human solid tumors. We examined several biochemical parameters that may contribute to the differential sensitivity of the cell lines used in our laboratory to the toxic effects of antitumor compounds. The tumor cell lines examined were of mouse (colon 38, L1210 leukemia, and C1498 leukemia) and human origin (CEM leukemia, CX1 colon, H116 colon, HCT8 colon and H125 lung). Quinone reductase activity was markedly different between leukemia and solid-tumor cell lines of either mouse or human origin, with increased activity being observed in the solid-tumor cell lines relative to the leukemia lines. GSH transferase activity also was generally increased in solid-tumor relative to leukemia cell lines. Superoxide dismutase activity and thiol levels were similar in leukemia and solid-tumor cell lines, except that thiol levels were very low in colon 38. Mouse cell lines from in vitro passage had somewhat higher activity of superoxide dismutase and thiol levels than did cells maintained in vivo, indicating relatively increased antioxidant defenses. The toxicity of 2,3-dimethoxy-1,4-naphthoquinone, a model quinone that exerts its toxic effects via production of reactive oxygen species, was significantly lower in mouse lines maintained in vitro than in those tested in vivo, whereas the toxicity of another quinone, menadione, was just slightly lower. Quinone reductase activity, GSH transferase activity, and thiol levels were significantly higher in the human lines than in the mouse lines. Accordingly, the toxicity of both quinones tended to be lower in the human lines than in the mouse lines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720171     DOI: 10.1007/BF00685727

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

Review 1.  Quinone chemistry and toxicity.

Authors:  T J Monks; R P Hanzlik; G M Cohen; D Ross; D G Graham
Journal:  Toxicol Appl Pharmacol       Date:  1992-01       Impact factor: 4.219

2.  Reduced glutathione in combination with superoxide dismutase as an important biological antioxidant defence mechanism.

Authors:  R Munday; C C Winterbourn
Journal:  Biochem Pharmacol       Date:  1989-12-15       Impact factor: 5.858

Review 3.  Is the P388 murine tumor no longer adequate as a drug discovery model?

Authors:  T H Corbett; F A Valeriote; L H Baker
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Detoxifying enzymes in human ovarian tissues: comparison of normal and tumor tissues and effects of chemotherapy.

Authors:  Z Djuric; V K Malviya; G Deppe; J M Malone; D L McGunagle; L K Heilbrun; B A Reading; W D Lawrence
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 5.  The role of glutathione-dependent enzymes in drug resistance.

Authors:  S M Black; C R Wolf
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

6.  Cytotoxicity of polycyclic aromatic hydrocarbon o-quinones in rat and human hepatoma cells.

Authors:  L Flowers-Geary; R G Harvey; T M Penning
Journal:  Chem Res Toxicol       Date:  1993 May-Jun       Impact factor: 3.739

7.  Menadione toxicity in two mouse liver established cell lines having striking genetic differences in quinone reductase activity and glutathione concentrations.

Authors:  R M Liu; D W Nebert; H G Shertzer
Journal:  Toxicol Appl Pharmacol       Date:  1993-09       Impact factor: 4.219

8.  Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.

Authors:  J H Lee; M Naito; M Nakajima; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.

Authors:  L Massaad; I de Waziers; V Ribrag; F Janot; P H Beaune; J Morizet; A Gouyette; G G Chabot
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

10.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.

Authors:  R D Traver; T Horikoshi; K D Danenberg; T H Stadlbauer; P V Danenberg; D Ross; N W Gibson
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

View more
  1 in total

1.  A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology.

Authors:  P J Bugelski; U Atif; S Molton; I Toeg; P G Lord; D G Morgan
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.